Summary of results by TNFi status at baseline
| TNFi-naïve | TNFi-IR | |||||
|---|---|---|---|---|---|---|
| SEC 300mg | SEC 150mg | PBO | SEC 300mg | SEC 150mg | PBO | |
| N | 67 | 63 | 63 | 33 | 37 | 35 |
| Pain VAS | ||||||
| Wk 16 | -27.8* | -25.1† | -11.3 | -18.2‡ | -21.1§ | -4.4 |
| Wk 104 | -29.6 | -28.3 | – | -19.3 | -20.4 | – |
| SF-36 bodily pain | ||||||
| Wk 16 | 23.8* | 25.4* | 8.6 | 18.3§ | 17.9§ | 5.2 |
| Wk 104 | 24.2 | 22.2 | – | 24.5 | 14.0¶ | – |
*P<0.0001; †P<0.001; §P<0.01; ‡P<0.05 vs. PBO. P-values and LS mean change at Wk 16 from MMRM analysis. Mean change at Wk 104 from observed data in n=57 (300mg) and 53 (150mg) for TNFi-naïve and n=29 (300mg) and 24 (150mg) for TNFi-IR; ¶n=26.